Clinical Trials
12 trialsNCT02689427 2026-05-12
Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT06099769 2026-02-25
A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT05057013 2025-08-11
A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours
Cancer Research UK
Phase 1/2 Active not recruiting
NCT02955394 2025-07-09
Preoperative Fulvestrant With or Without Enzalutamide in ER+/Her2- Breast Cancer
University of Colorado, Denver
Phase 2 Active not recruiting
NCT02750358 2025-06-22
Feasibility Study of Adjuvant Enzalutamide for the Treatment of Early Stage AR (+) Triple Negative Breast Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT03207529 2024-10-10
Alpelisib and Enzalutamide in Treating Patients With Androgen Receptor and PTEN Positive Metastatic Breast Cancer
M.D. Anderson Cancer Center
Phase 1 Completed
NCT02676986 2024-07-05
ARB
Queen Mary University of London
Phase 2 Completed
NCT03878524 2024-03-04
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
Phase 1 Terminated
NCT03310541 2023-05-06
AZD5363 in Patients With Advanced Solid Tumors Harboring AKT Mutations
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT04142060 2022-10-28
ARIANNA
SOLTI Breast Cancer Research Group
Phase 2 Terminated
NCT02457910 2022-08-22
Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer
Vanderbilt-Ingram Cancer Center
Phase 1/2 Terminated
NCT02953860 2021-05-14
Fulvestrant Plus Enzalutamide in ER+/Her2- Advanced Breast Cancer
University of Colorado, Denver
Phase 2 Completed